Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
PHP Toggle Menu

Category: 2026

Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases

MPOX

Published 26 May 2026
Categorized as 2025, 2025, 2026, 2026, Press release

Robust Protection Against Monkeypox Virus Mediated by a Novel Cell‑Line–Derived MVA Vaccine (TG-MVACL)

N. Silvestre, et al. World Congress on Infectious Diseases WCID 2026 Abstract available on WCID website – Download the abstract – Download the oral presentation

Published 26 May 2026
Categorized as -others, 2026, 2026, Publication

Transgene’s Combined General Meeting of May 22, 2026

AG 2026

Published 22 May 2026
Categorized as 2025, 2025, 2026, 2026, Press release

Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026

AG 2026

Published 4 May 2026
Categorized as 2025, 2025, 2026, 2026, Press release

Transgene Provides Business and Financial Update for Q1 2026

Q1 2026

Published 29 April 2026
Categorized as 2025, 2025, 2026, 2026, Press release

Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms

A. Agaoua et al. International Oncolytic Virus Conference 2026 – Download the Abstract – Download the Poster

Published 26 April 2026
Categorized as -others, 2026, 2026, Publication, publication key en

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

TG4050

Published 13 April 2026
Categorized as 2025, 2025, 2026, 2026, Myvac, Press release, TG4050

Transgene to Participate in Upcoming Investor Meetings

Investor meetings

Published 7 April 2026
Categorized as 2025, 2025, 2026, 2026, Press release

Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero

SAB Jan26

Published 23 January 2026
Categorized as -others, 2026, 2026, Press release

Posts pagination

Newer posts Page 1 Page 2
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
Menu